Cited by 134Cancer-related Molecular PathwaysCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

The DOI matches its Crossref record; 113 of the 116 references it cites were found in a registry or an index.

Collateral Lethality: A New Therapeutic Strategy in Oncology

Open access

Muller, Florian L., Aquilanti, Elisa A., DePinho, Ronald A.·2015·Trends in Cancer

DOI 10.1016/j.trecan.2015.10.002PMC PMC4746004

Open this paper in CoChat — free account

Abstract

Genomic deletion of tumor suppressor genes (TSG) is a rite of passage for virtually all human cancers. The synthetic lethal paradigm has provided a framework for the development of molecular targeted therapeutics that are functionally linked to the loss of specific TSG functions. In the course of genomic events that delete TSGs, a large number of genes with no apparent direct role in tumor promotion also sustain deletion as a result of chromosomal proximity to the target TSG. In this perspective, we review the novel concept of "collateral lethality", which has served to identify cancer-specific therapeutic vulnerabilities resulting from co-deletion of passenger genes neighboring TSG. The large number of collaterally deleted genes, playing diverse functions in cell homeostasis, offers a rich repertoire of pharmacologically targetable vulnerabilities presenting novel opportunities for the development of personalized anti-neoplastic therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.trecan.2015.10.002

Cites

113 of 113 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
A map of human genome variation from population-scale sequencing.
The 1000 Genomes Project Consortium (2010) · Nature · doi:10.1038/nature09534 · Cited by 7,877
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,432
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 1×
“Analysis of the minimal common deleted area led to the discovery of the cell cycle regulators (p16INK4A and p15INK4B) and the tumor suppressor (ARF) which are encoded by the CDKN2A/B locus [35].”
Background
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948 · cited 3×
“Di Fiore R, et al. RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis.”
Background
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Glioma Groups Based on 1p/19q, IDH , and TERT Promoter Mutations in Tumors
Eckel‐Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,981
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Multiple Intestinal Neoplasia Caused by a Mutation in the Murine Homolog of the APC Gene
Su, L.-K., Kinzler, K. W., Vogelstein, B., Preisinger, A. C., Moser, A. R., Luongo, C., Gould, K. A., & Dove, W. F. (1992) · Science · doi:10.1126/science.1350108 · Cited by 1,537
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1691 · Cited by 1,405
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
Gerlinger, M., Horswell, S. D., Larkin, J., Rowan, A., Salm, M., Varela, I., Fisher, R. A., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,236
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Two genetic hits (more or less) to cancer
Knudson, A. G. (2001) · Nature reviews. Cancer · doi:10.1038/35101031 · Cited by 1,122
A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations
Cawthon, R., Weiss, R. B., Xu, G., Viskochil, D. H., Culver, M., Stevens, J., Robertson, M. A., Dunn, D. M., Gesteland, R. F., O'Connell, P., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90253-b · Cited by 1,093
Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library
Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M. D. C., & Yusa, K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2800 · Cited by 1,064
Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis
Chen, S., Sanjana, N. E., Zheng, K., Shalem, O., Lee, K., Shi, X., Scott, D. A., Song, J., Pan, J. Q., Weissleder, R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.02.038 · Cited by 862
Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., & Siu, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.075 · Cited by 807
Evolution of genetic redundancy
Nowak, M. A., Boerlijst, M. C., Cooke, J., & Smith, J. M. (1997) · Nature · doi:10.1038/40618 · Cited by 760
Signatures of mutation and selection in the cancer genome
Bignell, G. R., Greenman, C. D., Davies, H., Butler, A. P., Edkins, S., Andrews, J. M., Buck, G., Chen, L., Beare, D., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08768 · Cited by 707
Innate versus learned odour processing in the mouse olfactory bulb
Kobayakawa, K., Kobayakawa, R., Matsumoto, H., Oka, Y., Imai, T., Ikawa, M., Okabe, M., Ikeda, T., Itohara, S., Kikusui, T., et al. (2007) · Nature · doi:10.1038/nature06281 · Cited by 659
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer
Welcsh, P. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.705 · Cited by 648
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Buller, H. R., Bethune, C., Bhanot, S., Gailani, D., Monia, B. P., Raskob, G. E., Segers, A. E. M., Verhamme, P. B., & Weitz, J. I. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405760 · Cited by 637
A loss-of-function RNA interference screen for molecular targets in cancer
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H. G., Lenz, G., Lam, L. T., Davé, S. S., Yang, L., Powell, J. I., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 606
Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.
REIFENBERGER, J., Reifenberger, G., Liu, L., James, C. D., Wechsler, W., & Collins, V. P. (1994) · PubMed Central · Cited by 601
LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin
Shackelford, D. B., Abt, E., Gerken, L., Vasquez, D. S., Seki, A., Leblanc, M., Wei, L., Fishbein, M. C., Czernin, J., Mischel, P. S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.008 · Cited by 585
Emerging insights into the molecular and cellular basis of glioblastomaPreprint
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012) · Genes & Development · doi:10.1101/gad.187922.112 · Cited by 573
Self-citation
Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality
Chan, D. A., Sutphin, P. D., Nguyen, P., Turcotte, S., Lai, E. W., Banh, A., Reynolds, G. E., Chi, J., Wu, J. J., Solow-Cordero, D. E., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002394 · Cited by 563
Exploring the Mode-of-Action of Bioactive Compounds by Chemical-Genetic Profiling in Yeast
Parsons, A. B., López, A., Givoni, I. E., Williams, D. E., Gray, C. A., Porter, J., Chua, G., Sopko, R., Brost, R. L., Ho, C.-H., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.040 · Cited by 512
Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase
Frezza, C., Zheng, L., Folger, O., Rajagopalan, K. N., MacKenzie, E. D., Jerby, L., Micaroni, M., Chaneton, B., Adam, J., Hedley, A., et al. (2011) · Nature · doi:10.1038/nature10363 · Cited by 503
Predicting selective drug targets in cancer through metabolic networks
Folger, O., Jerby‐Arnon, L., Frezza, C., Gottlieb, E., Ruppin, E., & Shlomi, T. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.35 · Cited by 480
Discovering Modes of Action for Therapeutic Compounds Using a Genome-Wide Screen of Yeast Heterozygotes
Lum, P. Y., Armour, C. D., Stepaniants, S. B., Cavet, G., Wolf, M. K., Butler, J. S., Hinshaw, J. C., Garnier, P., Prestwich, G. D., Leonardson, A. S., et al. (2004) · Cell · doi:10.1016/s0092-8674(03)01035-3 · Cited by 478
Liposomal siRNA nanocarriers for cancer therapy
Özpolat, B., Sood, A. K., & Lopez‐Berestein, G. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.12.008 · Cited by 455
INK4a/ARF: A multifunctional tumor suppressor locus
Sharpless, N. E. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.08.021 · Cited by 442
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer
Cheung, H. W., Cowley, G. S., Weir, B. A., Boehm, J. S., Rusin, S., Scott, J. A., East, A., Ali, L. D., Lizotte, P. H., Wong, T. C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109363108 · Cited by 423
Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers
Hoffman, G. R., Rahal, R., Buxton, F., Xiang, K., McAllister, G., Frias, E., Bagdasarian, L., Huber, J., Lindeman, A., Chen, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316793111 · Cited by 421
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
Monteleone, G., Neurath, M. F., Ardizzone, S., Sabatino, A. D., Fantini, M. C., Castiglione, F., Scribano, M. L., Armuzzi, A., Caprioli, F., Sturniolo, G. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407250 · Cited by 401
Most Human Non-GCIMP Glioblastoma Subtypes Evolve from a Common Proneural-like Precursor Glioma
Ozawa, T., Riester, M., Cheng, Y.-K., Huse, J. T., Squatrito, M., Helmy, K. Y., Charles, N. A., Michor, F., & Holland, E. C. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.005 · Cited by 393
Copy number alteration burden predicts prostate cancer relapse
Hieronymus, H., Schultz, N. D., Gopalan, A., Carver, B. S., Chang, M. T., Xiao, Y., Heguy, A., Huberman, K. H., Bernstein, M. L., Assel, M. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411446111 · Cited by 366
Passenger deletions generate therapeutic vulnerabilities in cancer
Muller, F. L., Colla, S., Aquilanti, E., Manzo, V. E., Genovese, G., Lee, J., Eisenson, D., Narurkar, R., Deng, P., Nezi, L., et al. (2012) · Nature · doi:10.1038/nature11331 · Cited by 339
Self-citation
Synthetic lethality: General principles, utility and detection using genetic screens in human cells
Nijman, S. M. B. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.11.024 · Cited by 334
Homozygous deletions within human chromosome band 9p21 in melanoma.
Fountain, J. W., Karayiorgou, M., Ernstoff, M. S., Kirkwood, J. M., Vlock, D. R., Titus-Ernstoff, L. T., Bouchard, B., Vijayasaradhi, S., Houghton, A. N., & Lahti, J. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10557 · Cited by 315
A Synthetic Lethality–Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1
Oike, T., Ogiwara, H., Tominaga, Y., Ito, K., Ando, O., Tsuta, K., Mizukami, T., Shimada, Y., Isomura, H., Komachi, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4593 · Cited by 305
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
Yoshimoto, M., da Cunha, I. W., Coudry, R. A., Fonseca, F. P., Torres, C., Soares, F. A., & Squire, J. A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603924 · Cited by 295
Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene / Allele-Specific Silencing of Mutant Huntingtin
Carroll, J. B., Warby, S. C., Southwell, A. L., Doty, C. N., Greenlee, S., Skotte, N. H., Hung, G., Bennett, C. F., Freier, S. M., & Hayden, M. R. (2011) · Molecular Therapy · doi:10.1038/mt.2011.201 · Cited by 293
A Molecule Targeting VHL-Deficient Renal Cell Carcinoma that Induces Autophagy
Turcotte, S., Chan, D. A., Sutphin, P. D., Hay, M. P., Denny, W. A., & Giaccia, A. J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.004 · Cited by 256
TP53 loss creates therapeutic vulnerability in colorectal cancer
Liu, Y., Zhang, X., Han, C., Wan, G., Huang, X., Ivan, C., Jiang, D., Rodriguez‐Aguayo, C., Lopez‐Berestein, G., Rao, P. H., et al. (2015) · Nature · doi:10.1038/nature14418 · Cited by 243
Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation
Wilson, B. G., Helming, K., Wang, X., Kim, Y., Vázquez, F., Jagani, Z., Hahn, W. C., & Roberts, C. W. M. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01372-13 · Cited by 243
Antisense oligonucleotide-based therapeutics for cancer
Dean, N. M., & Bennett, C. F. (2003) · Oncogene · doi:10.1038/sj.onc.1207231 · Cited by 242
The in vivo gene expression signature of oxidative stress
Han, E., Müller, F. L., Pérez, V., Qi, W., Liang, H., Liang, X., Fu, C., Doyle, E., Hickey, M., Cornell, J. E., et al. (2008) · Physiological Genomics · doi:10.1152/physiolgenomics.00239.2007 · Cited by 236
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Bertrand, F. E., Ludwig, D. E., Bäsecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.27 · Cited by 234
Chromosomal Abnormalities in Cancer
Fröhling, S., & Döhner, H. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0803109 · Cited by 229
Cancer Vulnerabilities Unveiled by Genomic Loss
Nijhawan, D., Zack, T. I., Ren, Y., Strickland, M. R., Lamothe, R. C., Schumacher, S. E., Tsherniak, A., Besche, H. C., Rosenbluh, J., Shehata, S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.07.023 · Cited by 225
ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
Gerber, D. E., & Minna, J. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.033 · Cited by 220
Recurrent Hemizygous Deletions in Cancers May Optimize Proliferative Potential
Solimini, N. L., Xu, Q., Mermel, C. H., Liang, A. C. T., Schlabach, M. R., Luo, J., Burrows, A. E., Anselmo, A. N., Bredemeyer, A. L., Li, M. Z., et al. (2012) · Science · doi:10.1126/science.1219580 · Cited by 214
RB1 in cancer: Different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis
Fiore, R. D., D’Anneo, A., Tesoriere, G., & Vento, R. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24329 · Cited by 211
Deletions of Interferon Genes in Acute Lymphoblastic Leukemia
Dı́az, M. O., Rubin, C. M., Harden, A. M., der Poel, S. Z.-V., Larson, R. A., Beau, M. M. L., & Rowley, J. D. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001113220202 · Cited by 211
Multiple knockout analysis of genetic robustness in the yeast metabolic network
Deutscher, D., Meilijson, I., Kupiec, M., & Ruppin, E. (2006) · Nature Genetics · doi:10.1038/ng1856 · Cited by 201
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
Dedes, K. J., Wilkerson, P. M., Wetterskog, D., Weigelt, B., Ashworth, A., & Reis-Filho, J. S. (2011) · Cell Cycle · doi:10.4161/cc.10.8.15273 · Cited by 191
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions
Xue, W., Kitzing, T. M., Roessler, S. K., Zuber, J. A., Krasnitz, A., Schultz, N. D., Revill, K., Weissmueller, S., Rappaport, A., Simon, J. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206062109 · Cited by 171
Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action
Baetz, K., McHardy, L. M., Gable, K., Tarling, T. E., Rebérioux, D., Bryan, J., Andersen, R. J., Dunn, T. M., Hieter, P., & Roberge, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307122101 · Cited by 171
Neuroblastoma consensus deletion maps to 1p36.1–2
Weith, A., Martinsson, T., Cziepluch, C., Brüderlein, S., Amler, L. C., Berthold, F., & Schwab, M. (1989) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870010209 · Cited by 169
High‐resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors
Hasselblatt, M., Isken, S., Linge, A., Eikmeier, K., Jeibmann, A., Oyen, F., Nagel, I., Richter, J., Bartelheim, K., Kordes, U., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22018 · Cited by 156
Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity
Bertino, J. R., Waud, W. R., Parker, W. B., & Lubin, M. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.7.14948 · Cited by 151
shRNA libraries and their use in cancer genetics
Bernards, R., Brummelkamp, T. R., & Beijersbergen, R. L. (2006) · Nature Methods · doi:10.1038/nmeth921 · Cited by 140
Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer
Gammal, A. T. E., Brüchmann, M., Zustin, J., Isbarn, H., Hellwinkel, O., Köllermann, J. W., Sauter, G., Simon, R., Wilczak, W., Schwarz, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1423 · Cited by 137
BRG1/SMARCA4 Inactivation Promotes Non–Small Cell Lung Cancer Aggressiveness by Altering Chromatin Organization
Orvis, T., Hepperla, A. J., Walter, V., Song, S., Simon, J. M., Parker, J. S., Wilkerson, M. D., Desai, N. R., Major, M. B., Hayes, D. N., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0061 · Cited by 137
Mig-6 controls EGFR trafficking and suppresses gliomagenesis
Ying, H., Zheng, H., Scott, K. L., Wiedemeyer, R., Yan, H., Lim, C., Huang, J. S., Dhakal, S., Ivanova, E. V., Xiao, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914930107 · Cited by 131
Self-citation
Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
Yamamoto, Y., Loriot, Y., Beraldi, E., Zhang, F., Wyatt, A. W., Nakouzi, N. A., Mo, F., Zhou, T., Kim, Y., Monia, B. P., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1108 · Cited by 129
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., & Solomon, B. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1415359 · Cited by 114
Widespread conservation of genetic redundancy during a billion years of eukaryotic evolution
Vavouri, T., Semple, J. I., & Lehner, B. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.08.005 · Cited by 109
Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions
Piaskowski, S., Bieńkowski, M., Stoczyńska-Fidelus, E., Stawski, R. S., Sieruta, M., Szybka, M., Papierz, W., Wolańczyk, M., Jaskólski, D. J., Liberski, P. P., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.27 · Cited by 107
microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF-β Signaling in Glioblastoma
Genovese, G., Ergün, A., Shukla, S. A., Campos, B., Hanna, J. A., Ghosh, P., Quayle, S. N., Rai, K., Colla, S., Ying, H., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0111 · Cited by 106
1p36 Tumor Suppression—A Matter of Dosage?
Henrich, K., Schwab, M., & Westermann, F. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2230 · Cited by 103
Genomic Profile of 320 Uveal Melanoma Cases: Chromosome 8p-Loss and Metastatic Outcome
Ewens, K. G., Kanetsky, P. A., Richards‐Yutz, J., Al-Dahmash, S. A., Luca, M. C. D., Bianciotto, C. G., Shields, C. L., & Ganguly, A. A. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12195 · Cited by 101
CAMTA1 , a 1p36 Tumor Suppressor Candidate, Inhibits Growth and Activates Differentiation Programs in Neuroblastoma Cells
Henrich, K., Bauer, T., Schulte, J. H., Ehemann, V., Deubzer, H. E., Gogolin, S., Muth, D., Fischer, M., Benner, A., König, R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3014 · Cited by 100
1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas
Ichimura, K., Vogazianou, A. P., Liu, L., Pearson, D. M., Bäcklund, L. M., Plant, K., Baird, K., Langford, C. F., Gregory, S. G., & Collins, V. P. (2007) · Oncogene · doi:10.1038/sj.onc.1210848 · Cited by 97
Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers
Yip, S. S. F., Iafrate, A. J., & Louis, D. N. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31815f65fb · Cited by 96
A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly
Krastev, D. B., Slabicki, M. M., Paszkowski‐Rogacz, M., Hubner, N. C., Junqueira, M., Shevchenko, A., Mann, M., Neugebauer, K. M., & Buchholz, F. (2011) · Nature Cell Biology · doi:10.1038/ncb2264 · Cited by 88
Reaction intermediate analogs for enolase
Anderson, V. E., Weiss, P. M., & Cleland, W. W. (1984) · Biochemistry · doi:10.1021/bi00307a038 · Cited by 84
Targeting Mutant p53 in Human Tumors
Lehmann, B. D., & Pietenpol, J. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.0412 · Cited by 74
Molecular mapping of chromosome 2 deletions in murine radiation-induced AML localizes a putative tumor suppressor gene to a 1.0 cM region homologous to human chromosome segment 11p11-12
Silver, A., Moody, J., Dunford, R., Clark, D., Ganz, S., Bulman, R. A., Bouffler, S. D., Finnon, P., Meijne, E. I. M., Huiskamp, R., et al. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199902)24:2 · Cited by 72
Molecular Dissection of the 5q Deletion in Myelodysplastic Syndrome
Ebert, B. L. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.04.010 · Cited by 71
Imaging genomic mapping of an invasive MRI phenotype predicts patient outcome and metabolic dysfunction: a TCGA glioma phenotype research group project
Colen, R. R., Vangel, M. G., Wang, J., Gutman, D. A., Hwang, S. N., Wintermark, M., Jain, R., Nicolas‐Jilwan, M., Chen, J. Y., Raghavan, P., et al. (2014) · BMC Medical Genomics · doi:10.1186/1755-8794-7-30 · Cited by 69
A Comparative Genomic Approach for Identifying Synthetic Lethal Interactions in Human Cancer
Deshpande, R., Asiedu, M. K., Klebig, M., Sutor, S., Kuzmin, E., Nelson, J., Piotrowski, J., Ho Shin, S., Yoshida, M., Costanzo, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3956 · Cited by 64
RNA Helicase A Is a Downstream Mediator of KIF1Bβ Tumor-Suppressor Function in Neuroblastoma
Chen, Z. X., Wallis, K., Fell, S. M., Sobrado, V. R., Hemmer, M. C., Ramsköld, D., Hellman, U., Sandberg, R., Kenchappa, R. S., Martinson, T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0362 · Cited by 57
Human RERE is localized to nuclear promyelocytic leukemia oncogenic domains and enhances apoptosis.
Waerner, T., Gardellin, P., Pfizenmaier, K., Weith, A., & Kraut, N. (2001) · PubMed · Cited by 52
Mice Heterozygous for Germ-line Mutations in Methylthioadenosine Phosphorylase ( MTAP ) Die Prematurely of T-Cell Lymphoma
Kadariya, Y., Yin, B., Tang, B., Shinton, S. A., Quinlivan, E. P., Xiang, H., Klein–Szanto, A. J., Al‐Saleem, T., Bassing, C. H., Hardy, R. R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0145 · Cited by 50
Synthetic lethality-based targets for discovery of new cancer therapeutics.
Weidle, U. H., Maisel, D., & Eick, D. (2011) · PubMed · Cited by 40
Selective Killing of Cancer Cells Based on Loss of Heterozygosity and Normal Variation in the Human Genome: A New Paradigm for Anticancer Drug Therapy
Basilion, J. P., Schievella, A. R., Burns, E., Rioux, P. P., Olson, J. C., Monia, B. P., Lemonidis, K. M., Stanton, V. P., & Housman, D. E. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.2.359 · Cited by 34
Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells
Tang, B., Testa, J. R., & Kruger, W. D. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21115 · Cited by 32
Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality
Wang, X., Liu, L., Montagna, C., Ried, T., & Deng, C.-X. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402105 · Cited by 31
Prediction of individualized therapeutic vulnerabilities in cancer from genomic profiles
Aksoy, B. A., Demir, E., Babur, Ö., Wang, W., Jing, X., Schultz, N. D., & Sander, C. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu164 · Cited by 31
Consequences of Nonadaptive Alterations in Cancer
Kamb, A. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-11-0732 · Cited by 31
Metachromatic leukodystrophy: Identification of the first deletion in exon 1 and nine novel point mutations in the arylsulfatase A gene
Draghia, R., Letourneur, F., Drugan, C., Manicom, J., Blanchot, C., Kahn, A., Poënaru, L., & Caillaud, C. (1997) · Human Mutation · doi:10.1002/(sici)1098-1004(1997)9:3 · Cited by 30
Syn-Lethality: An Integrative Knowledge Base of Synthetic Lethality towards Discovery of Selective Anticancer Therapies
Li, X., Mishra, S. K., Wu, M., Zhang, F., & Zheng, J. (2014) · BioMed Research International · doi:10.1155/2014/196034 · Cited by 27
Status of Methylthioadenosine Phosphorylase and its Impact on Cellular Response to l-Alanosine and Methylmercaptopurine Riboside in Human Soft Tissue Sarcoma Cells
Li, W., Su, D., Mizobuchi, H., Martin, D. S., Gu, B., Gorlick, R. G., Cole, P. D., & Bertino, J. R. (2004) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/0965040041292332 · Cited by 27
Targeting Rb inactivation in cancers by synthetic lethality.
Gordon, G. M., & Du, W. (2011) · PubMed · Cited by 20
Inhibition of Mutated BRAF in Melanoma
Kim, T., Kim, J., & Lee, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1010755 · Cited by 18
Syn-Lethality: An integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies
Li, X., Mishra, S. K., Wu, M., Zhang, F., & Zheng, J. (2013) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2013.6732609 · Cited by 17
Methylthioadenosine (MTA) Rescues Methylthioadenosine Phosphorylase (MTAP)-Deficient Tumors from Purine Synthesis Inhibition in Vivo via Non-Autonomous Adenine Supply
Ruefli-Brasse, A. A., Sakamoto, D., Orf, J. N., Rong, M., Shi, J., Carlson, T., Quon, K. C., Kamb, A., & Wickramasinghe, D. (2011) · Journal of Cancer Therapy · doi:10.4236/jct.2011.24072 · Cited by 12
Imatinib in Chronic Myeloid Leukemia
Krause, S. W., & Holler, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmc063767 · Cited by 5
JAK Inhibition in Myelofibrosis
Arellano‐Rodrigo, E., & Álvarez‐Larrán, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1011635 · Cited by 2
An In Vivo Genome-Scale CRISPR Screen Defines Regulators of Metastasis
(2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2015-050 · Cited by 1

Sorted by citations

Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Self-citation
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis
Marjon, K., Cameron, M. J., Quang, P., Clasquin, M. F., Mandley, E., Kunii, K., McVay, M., Choe, S., Kernytsky, A., Gross, S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.043 · Cited by 485
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 434

See all 134

Authors: Muller, F. L., Aquilanti, E. A., & DePinho, R. A.
Affiliations: Brigham and Women's Hospital (US)
The University of Texas MD Anderson Cancer Center (US)
Corresponding author: DePinho, Ronald A.
ORCID: Aquilanti, Elisa A.
DePinho, Ronald A.
Venue: Trends in Cancer
Publisher: Elsevier BV
Published: 2015-11
Volume: 1
Issue: 3
Pages: 161-173
ISSN: 2405-8025 (ISSN-L)
2405-8033
DOI: 10.1016/j.trecan.2015.10.002
PMC: PMC4746004
OpenAlex: W2179093278
Cited by: 132
References: 116
Citations by year: 2026: 10 · 2025: 12 · 2024: 10 · 2023: 9 · 2022: 18 · 2021: 14 · 2020: 17 · 2019: 15 · 2018: 11 · 2017: 10 · 2016: 6
FWCI: 0.97
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Trends in cancer (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (P01CA095616, P50CA127001)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: synthetic lethality, tumor suppressor, passenger genes, precision oncology, targeted cancer therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Collateral Lethality: A New Therapeutic Strategy in Oncology

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks